Publications by authors named "Thomas Butt"

Claim this Profile
H
Health State Utilities for Achondroplasia: A Time Trade-Off Study.
Claudia Mighiu, George Morgan, Rashmi Bharali, Thomas Butt, Christina Due

Value Health· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants with CLN2 Disease Treated with Cerliponase Alfa.
Christina Due, Jennifer Quinn, Paul Gissen, Angela Schulz, Nicola Specchio, Thomas Butt

Healthcare (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data.
Nicola Specchio, Paul Gissen, Emily de Los Reyes, Andrew Olaye, Charlotte Camp, Thomas Butt

PLoS One· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden and Treatment of Achondroplasia: A Systematic Literature Review.
Molly C Murton, Emma L A Drane, Danielle M Goff-Leggett, Renée Shediac, Jamie O'Hara, Thomas J Butt

Adv Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration - a MACUSTAR study report.
Jan Henrik Terheyden, Susanne G Pondorfer, Charlotte Behning, Moritz Berger, Jill Carlton, Thomas Butt

Br J Ophthalmol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns and determinants of incident cataract surgery in China from 2011 to 2015 using a nationally representative longitudinal database.
Catherine Jan, Jin Xin, Yanhui Dong, Thomas Butt, Robert Chang

BMJ Open· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study.
Mohamad Maghnie, Oliver Semler, Encarna Guillen-Navarro, Angelo Selicorni, Karen E Heath, Thomas Butt

Orphanet J Rare Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].
Domenico Moro, Michael Schlander, Harry Telser, Oriol Sola-Morales, Michael David Clark, Thomas Butt

Expert Rev Pharmacoecon Outcomes Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study.
Ravi Savarirayan, Wagner Baratela, Thomas Butt, Valérie Cormier-Daire, Melita Irving

Orphanet J Rare Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical disputes and patient satisfaction in China: How does hospital management matter?
Mengxiao Wang, Gordon Guo-En Liu, Nicholas Bloom, Hanqing Zhao, Thomas Butt

Int J Health Plann Manage· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economics of vision impairment and its leading causes: A systematic review.
Ana Patricia Marques, Jacqueline Ramke, John Cairns, Thomas Butt, Justine H Zhang

EClinicalMedicine· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2).
Paul Gissen, Nicola Specchio, Andrew Olaye, Mohit Jain, Thomas Butt

Orphanet J Rare Dis· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global economic productivity losses from vision impairment and blindness.
Ana Patricia Marques, Jacqueline Ramke, John Cairns, Thomas Butt, Justine H Zhang

EClinicalMedicine· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the global cost of vision impairment and its major causes: protocol for a systematic review.
Ana Patricia Marques, Jacqueline Ramke, John Cairns, Thomas Butt, Justine H Zhang

BMJ Open· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of mediation in solving medical disputes in China.
Mengxiao Wang, Gordon G Liu, Hanqing Zhao, Thomas Butt, Maorui Yang

BMC Health Serv Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Productivity Losses and Their Explanatory Factors Amongst People with Impaired Vision.
Ana Patricia Marques, Antonio Filipe Macedo, Pedro Lima Ramos, Laura Hernandez Moreno, Thomas Butt

Ophthalmic Epidemiol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and health burden of the undiagnosed population at risk of chronic obstructive pulmonary disease in China.
Marco Koch, Thomas Butt, Wudong Guo, Xue Li, Yirong Chen

BMC Public Health· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring the Benefits of Decision Aids for Economic Evaluation.
Thomas Butt

Pharmacoecon Open· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Taking stock of cost-effectiveness analysis of healthcare in China.
Thomas Butt, Gordon G Liu, David D Kim, Peter J Neumann

BMJ Glob Health· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of informal care by people with vision impairment.
Ana Patricia Marques, Antonio Filipe Macedo, Laura Hernandez-Moreno, Pedro Lima Ramos, Thomas Butt

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.
Aaron Y Lee, Thomas Butt, Emily Chew, Elvira Agron, Traci E Clemons

Br J Ophthalmol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D.
Brendan Mulhern, Joshua Pink, Donna Rowen, Simon Borghs, Thomas Butt

Value Health· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health State Utility Values for Age-Related Macular Degeneration: Review and Advice.
Thomas Butt, Adnan Tufail, Gary Rubin

Appl Health Econ Health Policy· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discounting role in cost-effectiveness of HPV vaccination by Starkie Camejo et al. (Public Health Vol 129(7):989-92).
Thomas Butt, Rosybel Drury, Nathalie Largeron

Public Health· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
Thomas Butt, Aaron Lee, Cecilia Lee, Adnan Tufail,

BMJ Open· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis